Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis

BACKGROUND: The best investigational drug to treat cystic fibrosis (CF) patients with the most common CF-causing mutation (F508del) is VX-809 (lumacaftor) which recently succeeded in Phase III clinical trial in combination with ivacaftor. This corrector rescues F508del-CFTR from its abnormal intrace...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EBioMedicine
Hauptverfasser: Awatade, Nikhil T., Uliyakina, Inna, Farinha, Carlos M., Clarke, Luka A., Mendes, Karina, Solé, Amparo, Pastor, Juan, Ramos, Maria Margarida, Amaral, Margarida D.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2014
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4484512/
https://ncbi.nlm.nih.gov/pubmed/26137539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2014.12.005
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge